Drugs / EZN-3042
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01186328 | Aug 2010 → Jan 2012 | T-cell acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EZN-3042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01186328 ↗ |
| Action | Inhibit | “highly effective at blocking survivin and inhibiting survivin protein expression” NCT01186328 ↗ |
| Route | Intravenous | “To be given as a 2 hour intravenous infusion” NCT01186328 ↗ |